A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

Orion Corporation, Orion Pharma

Summary

Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: 1. Male or female subjects ≥18 years old 2. Subjects must have histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumour of the kind listed below that is not amenable for treatment with curative intent, e.g.: Part 1: * mesothelioma * epithelioid hemangioendothelioma (EHE) * cholangiocarcinoma (CCA) * head and neck squamous cell carcinoma (HNSCC) * non-small cell lung carcinoma (NSCLC) * colorectal cancer (CRC) * hepatocellular cancer (HCC) * castration-resistant prostate cancer (CRPC) * meningioma * any o…

Locations (20)

Valkyrie Clinical Trials
Los Angeles, California
david.berz@valkyrieclinicaltrials.com
UC Irvine Health
Orange, California
fdayyani@hs.uci.edu
Siteman Cancer Center
St Louis, Missouri
ayseece@wustl.edu
Memorial Sloan Kettering Cancer Center
New York, New York
gounderm@mskcc.org
Westchester Medical Center
Valhalla, New York
marjorie.zauderer@wmchealth.org
Jefferson University Hospital
Philadelphia, Pennsylvania
sarah.gordon@jefferson.edu

Summary

Eligibility

Interventions

Locations (20)